Oxford Genetics, our history
Our discoveries and processes enable pharmaceutical and biotechnology companies unparalleled performance in developing new commercially viable drug therapies and vaccines.
Founded in 2011 by Dr Ryan Cawood, CEO.
Ryan started the business with Professor Leonard Seymour (non-executive director), on completion of his PhD at the University of Oxford.
OXGENE grew from the foundations of patented DNA engineering methods into a synthetic biology company focused on precise and replicable engineering of mammalian cell lines to accelerate the discovery, development and production of innovative proprietary technologies. The organisation offers a suite of novel solutions for gene therapy drug discovery, antibody therapy development and CRISPR gene editing.
In the past few years OXGENE has gone from strength to strength. We now work with several high-profile customers in the pharmaceutical and biotech industry. The unique ability to work across a broad spectrum of biologics means that our scientists are experts in bringing innovative solutions to the challenges of biotechnology engineering.